LSA
XERS icon

Leonteq Securities AG’s Xeris Biopharma Holdings XERS Stock Holding History

Leonteq Securities AG’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-21,000
Closed -$61.5K – 1350
2021
Q4 		$61.5K Buy
+21,000
New +$45.4K ﹤0.01% 860

Other funds holding XERS

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Leonteq Securities AG's XERS Position: Q1 2022 in Review

Leonteq Securities AG sold out of Xeris Biopharma Holdings (XERS) in Q1 2022, closing a stake of 21,000 shares — an estimated $61.5K sold.

Leonteq Securities AG first reported a position in XERS in Q4 2021 and held it in 1 quarter. The position peaked at $61.5K in Q4 2021. 103 funds tracked by Wall St. Rank hold XERS as of Q1 2022.

  • Leonteq Securities AG reported no remaining Xeris Biopharma Holdings position as of Q1 2022 after selling out during the quarter.
  • Leonteq Securities AG sold 21,000 Xeris Biopharma Holdings shares in Q1 2022, an estimated $61.5K.
  • Leonteq Securities AG first reported a position in Xeris Biopharma Holdings in Q4 2021 and held it in 1 quarter.
  • Leonteq Securities AG's Xeris Biopharma Holdings position peaked at $61.5K in Q4 2021.
  • 103 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2022.

Based on Leonteq Securities AG's 13F filing for Q1 2022, filed 26 Mar 2026.